ENTRY       1029              CDS       T01001
NAME        CDKN2A, ARF, CDK4I, CDKN2, CMM2, INK4, INK4A, MLM, MTS-1, MTS1, P14, P14ARF, P16, P16-INK4A, P16INK4, P16INK4A, P19, P19ARF, TP16
DEFINITION  (RefSeq) cyclin dependent kinase inhibitor 2A
ORTHOLOGY   K06621  cyclin-dependent kinase inhibitor 2A
ORGANISM    hsa  Homo sapiens (human)
PATHWAY     hsa01522  Endocrine resistance
            hsa01524  Platinum drug resistance
            hsa04110  Cell cycle
            hsa04115  p53 signaling pathway
            hsa04218  Cellular senescence
            hsa05166  HTLV-I infection
            hsa05200  Pathways in cancer
            hsa05203  Viral carcinogenesis
            hsa05206  MicroRNAs in cancer
            hsa05212  Pancreatic cancer
            hsa05214  Glioma
            hsa05218  Melanoma
            hsa05219  Bladder cancer
            hsa05220  Chronic myeloid leukemia
            hsa05223  Non-small cell lung cancer
DISEASE     H00004  Chronic myeloid leukemia (CML)
            H00008  Burkitt lymphoma
            H00009  Adult T-cell leukemia
            H00014  Non-small cell lung cancer
            H00015  Malignant pleural mesothelioma
            H00016  Oral cancer
            H00017  Esophageal cancer
            H00019  Pancreatic cancer
            H00022  Bladder cancer
            H00025  Penile cancer
            H00036  Osteosarcoma
            H00038  Malignant melanoma
            H00040  Squamous cell carcinoma
            H00042  Glioma
            H00046  Cholangiocarcinoma
            H00047  Gallbladder cancer
            H00048  Hepatocellular carcinoma
            H00054  Nasopharyngeal cancer
            H00055  Laryngeal cancer
            H00409  Type II diabetes mellitus
            H01463  Mycosis fungoides
            H01464  Mantle cell lymphoma
            H01508  Salivary gland cancer
            H01509  Tonsillar cancer
            H01513  Retinoblastoma
            H01556  Meningioma
BRITE       KEGG Orthology (KO) [BR:hsa00001]
             Cellular Processes
              Cell growth and death
               04110 Cell cycle
                1029 (CDKN2A)
               04115 p53 signaling pathway
                1029 (CDKN2A)
               04218 Cellular senescence
                1029 (CDKN2A)
             Human Diseases
              Cancers
               05200 Pathways in cancer
                1029 (CDKN2A)
               05206 MicroRNAs in cancer
                1029 (CDKN2A)
               05203 Viral carcinogenesis
                1029 (CDKN2A)
               05212 Pancreatic cancer
                1029 (CDKN2A)
               05214 Glioma
                1029 (CDKN2A)
               05220 Chronic myeloid leukemia
                1029 (CDKN2A)
               05218 Melanoma
                1029 (CDKN2A)
               05219 Bladder cancer
                1029 (CDKN2A)
               05223 Non-small cell lung cancer
                1029 (CDKN2A)
              Infectious diseases
               05166 HTLV-I infection
                1029 (CDKN2A)
              Drug resistance
               01524 Platinum drug resistance
                1029 (CDKN2A)
               01522 Endocrine resistance
                1029 (CDKN2A)
POSITION    9p21.3
MOTIF       Pfam: Ank_5 Ank_4 Ank_2 Ank
DBLINKS     NCBI-GeneID: 1029
            NCBI-ProteinID: NP_000068
            OMIM: 600160
            HGNC: 1787
            Ensembl: ENSG00000147889
            Vega: OTTHUMG00000019686
            Pharos: P42771(Tbio)
            UniProt: P42771 K7PML8
STRUCTURE   PDB: 1BI7 1DC2 1A5E 2A5E
AASEQ       156
            MEPAAGSSMEPSADWLATAAARGRVEEVRALLEAGALPNAPNSYGRRPIQVMMMGSARVA
            ELLLLHGAEPNCADPATLTRPVHDAAREGFLDTLVVLHRAGARLDVRDAWGRLPVDLAEE
            LGHRDVARYLRAAAGGTRGSNHARIDAAEGPSDIPD
NTSEQ       471
            atggagccggcggcggggagcagcatggagccttcggctgactggctggccacggccgcg
            gcccggggtcgggtagaggaggtgcgggcgctgctggaggcgggggcgctgcccaacgca
            ccgaatagttacggtcggaggccgatccaggtcatgatgatgggcagcgcccgagtggcg
            gagctgctgctgctccacggcgcggagcccaactgcgccgaccccgccactctcacccga
            cccgtgcacgacgctgcccgggagggcttcctggacacgctggtggtgctgcaccgggcc
            ggggcgcggctggacgtgcgcgatgcctggggccgtctgcccgtggacctggctgaggag
            ctgggccatcgcgatgtcgcacggtacctgcgcgcggctgcggggggcaccagaggcagt
            aaccatgcccgcatagatgccgcggaaggtccctcagacatccccgattga
///
